home / stock / idra / idra quote
Last: | $0.425 |
---|---|
Change Percent: | 12.01% |
Open: | $0.4768 |
Close: | $0.425 |
High: | $0.51 |
Low: | $0.42 |
Volume: | 366,686 |
Last Trade Date Time: | 01/17/2023 03:40:41 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.425 | $0.4768 | $0.425 | $0.51 | $0.42 | 366,686 | 01-17-2023 |
$0.5419 | $0.56 | $0.5419 | $0.5601 | $0.5401 | 51,069 | 01-16-2023 |
$0.5419 | $0.56 | $0.5419 | $0.560051 | $0.5401 | 51,069 | 01-13-2023 |
$0.55 | $0.5294 | $0.55 | $0.56 | $0.5 | 127,331 | 01-12-2023 |
$0.5001 | $0.4628 | $0.5001 | $0.5341 | $0.4341 | 339,619 | 01-11-2023 |
$0.4628 | $0.65 | $0.4628 | $0.7 | $0.431 | 548,499 | 01-10-2023 |
$0.655 | $0.7037 | $0.655 | $0.714 | $0.6544 | 529,795 | 01-09-2023 |
$0.7099 | $0.65 | $0.7099 | $0.72 | $0.6311 | 552,664 | 01-06-2023 |
$0.66 | $0.572 | $0.66 | $0.68 | $0.5405 | 633,766 | 01-05-2023 |
$0.5569 | $0.45 | $0.5569 | $0.56 | $0.45 | 627,899 | 01-04-2023 |
$0.4609 | $0.3496 | $0.4609 | $0.4833 | $0.3369 | 858,482 | 01-03-2023 |
$0.35 | $0.297 | $0.35 | $0.36 | $0.297 | 385,036 | 01-02-2023 |
$0.35 | $0.297 | $0.35 | $0.36 | $0.297 | 385,036 | 12-30-2022 |
$0.279 | $0.28 | $0.279 | $0.2895 | $0.2705 | 134,370 | 12-29-2022 |
$0.2609 | $0.22 | $0.2609 | $0.27 | $0.215 | 188,172 | 12-28-2022 |
$0.2311 | $0.25 | $0.2311 | $0.25 | $0.221 | 72,324 | 12-27-2022 |
$0.2418 | $0.2752 | $0.2418 | $0.2752 | $0.2401 | 46,422 | 12-26-2022 |
$0.2418 | $0.2752 | $0.2418 | $0.2752 | $0.2401 | 46,422 | 12-23-2022 |
$0.275 | $0.2454 | $0.275 | $0.2809 | $0.235 | 160,951 | 12-22-2022 |
$0.25 | $0.2629 | $0.25 | $0.2699 | $0.25 | 117,977 | 12-21-2022 |
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...